Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Systems modeling of the role of interleukin-21 in the maintenance of effector CD4+ T cell responses during chronic Helicobacter pylori infection.

mBio | 2014

The development of gastritis during Helicobacter pylori infection is dependent on an activated adaptive immune response orchestrated by T helper (Th) cells. However, the relative contributions of the Th1 and Th17 subsets to gastritis and control of infection are still under investigation. To investigate the role of interleukin-21 (IL-21) in the gastric mucosa during H. pylori infection, we combined mathematical modeling of CD4(+) T cell differentiation with in vivo mechanistic studies. We infected IL-21-deficient and wild-type mice with H. pylori strain SS1 and assessed colonization, gastric inflammation, cellular infiltration, and cytokine profiles. Chronically H. pylori-infected IL-21-deficient mice had higher H. pylori colonization, significantly less gastritis, and reduced expression of proinflammatory cytokines and chemokines compared to these parameters in infected wild-type littermates. These in vivo data were used to calibrate an H. pylori infection-dependent, CD4(+) T cell-specific computational model, which then described the mechanism by which IL-21 activates the production of interferon gamma (IFN-γ) and IL-17 during chronic H. pylori infection. The model predicted activated expression of T-bet and RORγt and the phosphorylation of STAT3 and STAT1 and suggested a potential role of IL-21 in the modulation of IL-10. Driven by our modeling-derived predictions, we found reduced levels of CD4(+) splenocyte-specific tbx21 and rorc expression, reduced phosphorylation of STAT1 and STAT3, and an increase in CD4(+) T cell-specific IL-10 expression in H. pylori-infected IL-21-deficient mice. Our results indicate that IL-21 regulates Th1 and Th17 effector responses during chronic H. pylori infection in a STAT1- and STAT3-dependent manner, therefore playing a major role controlling H. pylori infection and gastritis. Importance: Helicobacter pylori is the dominant member of the gastric microbiota in more than 50% of the world's population. H. pylori colonization has been implicated in gastritis and gastric cancer, as infection with H. pylori is the single most common risk factor for gastric cancer. Current data suggest that, in addition to bacterial virulence factors, the magnitude and types of immune responses influence the outcome of colonization and chronic infection. This study uses a combined computational and experimental approach to investigate how IL-21, a proinflammatory T cell-derived cytokine, maintains the chronic proinflammatory T cell immune response driving chronic gastritis during H. pylori infection. This research will also provide insight into a myriad of other infectious and immune disorders in which IL-21 is increasingly recognized to play a central role. The use of IL-21-related therapies may provide treatment options for individuals chronically colonized with H. pylori as an alternative to aggressive antibiotics.

Pubmed ID: 25053783 RIS Download

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCCIH NIH HHS, United States
    Id: K01AT007324
  • Agency: NCCIH NIH HHS, United States
    Id: K01 AT007324
  • Agency: NCI NIH HHS, United States
    Id: P30 CA68485
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK058404
  • Agency: NCCIH NIH HHS, United States
    Id: R01 AT004821
  • Agency: NIAID NIH HHS, United States
    Id: HHSN272201000056C
  • Agency: BLRD VA, United States
    Id: I01 BX001453
  • Agency: NCI NIH HHS, United States
    Id: P30 CA068485
  • Agency: NIDDK NIH HHS, United States
    Id: P30DK058404
  • Agency: NIDDK NIH HHS, United States
    Id: R01DK053620
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK053620
  • Agency: NCI NIH HHS, United States
    Id: P01 CA028842
  • Agency: NCI NIH HHS, United States
    Id: P01 CA116087
  • Agency: BLRD VA, United States
    Id: I01 BX000915

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

B6.129S-Il21tm1Lex/Mmucd (organism)

RRID:MMRRC_032800-UCD

Mus musculus with name B6.129S-Il21tm1Lex/Mmucd from MMRRC.

View all literature mentions

B6;129S5-Il21tm1Lex/Mmucd (organism)

RRID:MMRRC_011723-UCD

Mus musculus with name B6;129S5-Il21tm1Lex/Mmucd from MMRRC.

View all literature mentions